Pharmaceuticals, Biotechnology & Life Sciences

CEO Thomas Schoenherr’s modest buy of Tempus AI stock signals renewed confidence in its AI‑driven diagnostics, hinting at a potential upside amid market volatility.

Exagen CEO’s tax‑related sale is routine, but insider selling trends highlight cautious management—investors should watch Q4 earnings for real impact.

Insider buying boosts optimism for Axsome’s pipeline, as Mark Coleman’s 6,250‑share purchase signals confidence in commercial growth and Phase 3 trials.

Insider buying at Personalis Inc. shows CFO Tachibana’s confidence; zero‑cost option exercise hints at future growth but current negative earnings warn of risk.

Insightful insider sale of Xeris Biopharma shares shows cautious liquidity strategy amid recent revenue beat, urging investors to watch upcoming clinical milestones for true upside.

Alkermes insider buying signals management confidence amid Avadel acquisition; learn what Parisi Samuel Joseph’s trades mean for investors.

Avantor insider moves: EVP Claudius sells 2,376 shares amid stock volatility – what it means for investor confidence and future prospects.

CEO Nello Mainolfi’s 10b5‑1 trades show deep confidence in Kymera Therapeutics—buying at lows, selling as the stock climbs—offering investors a bullish insider insight into its protein‑degradation pipeline.

Insider buying and RSU sales by Supernus CFO signal cautious optimism ahead of potential pipeline milestones, hinting at a strategic liquidity move.

Arvinas insider sales are routine, not a red‑flag. Loomis’s tax‑sale shows standard RSU settlement; the company’s biotech pipeline remains a key focus.